GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » USCOM Ltd (ASX:UCM) » Definitions » YoY EBITDA Growth

USCOM (ASX:UCM) YoY EBITDA Growth : 33.33% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is USCOM YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. USCOM's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 33.33%.

USCOM's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.00.


USCOM YoY EBITDA Growth Historical Data

The historical data trend for USCOM's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

USCOM YoY EBITDA Growth Chart

USCOM Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.46 50.00 25.00 -166.67 -50.00

USCOM Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -100.00 -50.00 -50.00 33.33

USCOM YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

USCOM's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (A: Jun. 2023 )
=(EBITDA per Share (A: Jun. 2023 )-EBITDA per Share (A: Jun. 2022 ))/ | EBITDA per Share (A: Jun. 2022 ) |
=(-0.012--0.008)/ | -0.008 |
=-50.00 %

USCOM's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.004--0.006)/ | -0.006 |
=33.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


USCOM YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of USCOM's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


USCOM (ASX:UCM) Business Description

Traded in Other Exchanges
N/A
Address
Level 8, 66 Clarence Street, Suite 2, Sydney, NSW, AUS, 2000
USCOM Ltd is engaged in the development, design, manufacture, and marketing of premium non-invasive cardiovascular and pulmonary medical devices. The company's geographical segment includes Australia, Asia, America, Europe, and Other regions. It generates maximum revenue from Australia. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, SPIROSONIC, a pulmonary function testing device based on multi-path ultrasound technology and the VENTITEST and VENTITEST-S ultrasonic ventilator calibration devices for optimizing respiratory device performance.

USCOM (ASX:UCM) Headlines

No Headlines